Is Krsnaa Diagnostics (KRSNAA) overvalued or fairly valued?

MarketChacha shows Krsnaa Diagnostics's valuation in context — a forward P/E of about 12.0, a price-to-book of about 1.8 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Krsnaa Diagnostics's revenue?

Krsnaa Diagnostics reported revenue of ₹773 Cr for FY2026, with net profit of ₹101 Cr, per official filings.

What is the share price of Krsnaa Diagnostics (KRSNAA)?

Krsnaa Diagnostics last traded at ₹541.70 (-0.9% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Krsnaa Diagnostics

KRSNAA · NSE · Healthcare · India

₹541.70-0.9%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 10:00 AM

Snapshot

TickerKRSNAA

ExchangeNSE

SectorHealthcare

IndustryDiagnostics & Research

CountryIndia

CEOMr. Mitesh Dave

HeadquartersPune, India

Market cap₹1,757 Cr

P/B1.8

Volume28.37K

Websitekrsnaadiagnostics.com

Filings tracked0

About Krsnaa Diagnostics

Krsnaa Diagnostics Limited provides diagnostic services in India. It offers a range radiology services, including computed tomography scans, magnetic resonance imaging, X-rays, and ultrasound and advanced imaging; pathology services, such as laboratory, and home collection and preventive health; and teleradiology and telepathology services. The company also provides other diagnostics services, such as ophthalmic test, mammography, dental imaging, stress test, dual-energy X-ray absorptiometry scan, and bone mineral density test. It serves individual patients, government clients, corporate clients, hospitals, clinics, private practitioner, and other healthcare providers. Krsnaa Diagnostics Limited was incorporated in 2010 and is based in Pune, India.

Profile as reported by Yahoo Finance.

Who owns it

Promoters45.7%
Institutions13.5%
Public & other40.8%

12 institutional holders

As reported by Yahoo Finance. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend12.8% → 13.1%

Margin has held broadly steady over the period — stable profitability.

Growth qualityrev 17% · PAT 18%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next fiscal year

Rev ₹1,129 Cr · EPS 45.25

Est. earnings growth +51.0%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

₹515.0052-wk range₹894.40

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 4

Market cap

₹1,757 Cr

Day change

-0.9%

Fwd P/E

12.0

P/B

1.8

Div yield

0.50%

Beta

0.06

Revenue (FY2026)

₹773 Cr

Net margin

13.1%

Revenue CAGR (3y)

+16.6%

Profit CAGR (3y)

+17.8%

Net profit (FY2026)

₹101 Cr

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about KRSNAA

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹773 Cr	₹101 Cr	13.1%
FY2025	₹717 Cr	₹78 Cr	10.8%
FY2024	₹620 Cr	₹57 Cr	9.2%
FY2023	₹487 Cr	₹62 Cr	12.8%

Quarterly

Period	Revenue	Net profit	Net margin
2026Q1	₹193 Cr	₹42 Cr	21.7%
2025Q4	₹181 Cr	₹15 Cr	8.4%
2025Q3	₹206 Cr	₹24 Cr	11.6%
2025Q2	₹193 Cr	₹21 Cr	10.6%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.